Novartis AG

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 (2018) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Characteristics and healthcare situation of adult patients with tuberous sclerosis complex in German epilepsy centers (2018) Hamer H, Pfaefflin M, Baier H, Boesebeck F, Franz M, Holtkamp M, Kurlemann G, et al. Journal article Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition (2018) Siebzehnrubl FA, Reber KA, Urbach YK, Schulze-Krebs A, Canneva F, Moceri S, Habermeyer J, et al. Journal article The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: Case finding, screening and characteristics of eligible participants (2018) Marzetti E, Cesari M, Calvani R, Msihid J, Tosato M, Rodriguez-Manas L, Lattanzio F, et al. Journal article Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL (2018) Boegemann M, Bedke J, Schostak M, Welslau M, Hering-Schubert C, Wolf T, Schleicher J, et al. Conference contribution Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment (2018) Yao JC, Fazio N, Li D, Pavel ME, Strosberg J, Bergsland E, Ruszniewski P, et al. Conference contribution Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials (2018) Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, et al. Conference contribution Secukinumab Efficacy in Psoriatic Arthritis: Individual Patient Meta-Analysis of Four Phase 3 Trials in 2049 Patients (2018) Gottlieb AB, Mease PJ, Kirkham B, Nash P, Balsa A, Combe B, Rech J, et al. Conference contribution SECUKINUMAB EFFICACY IN PSORIATIC ARTHRITIS PATIENTS WITH OR WITHOUT ENTHESITIS AT BASELINE - POOLED ANALYSIS FROM TWO PHASE-III TRIALS OVER 2 YEARS (2018) Wallman JK, Schett G, Mcinnes IB, Quebe-Fehling E, Rasouliyan L, Pricop L, Fasth AE, Gaillez C Conference contribution